ecrin-mdr-crcClinical2008Rectal NeoplasmsLocally advanced rectal cancerColorectal CancerRectal NeoplasmsColorectal CancerLocally Advanced Rectal CancerInterventionalhttps://newmdr.ecrin.org/Study/2064382Slovakia10CapecitabineECRIN MDRCompletedfalseA Study of Xeloda (Capecitabine) Plus Radiotherapy in Participants With Locally Advanced Rectal CancerThis single arm study will assess the efficacy and safety of treatment with Xeloda plus standard pelvic radiotherapy in participants with locally advanced rectal cancer. Eligible participants will receive Xeloda 825mg/m^2 orally twice daily plus standard radiotherapy for 5 weeks, followed by surgery within 6 weeks after completion of treatment. The anticipated time on study treatment is < 3 months, and the target sample size is < 100 individuals.2008-10-152064382NCT007967182008-003980-38